#USA #Drug Development #biotechnology #Pleasanton #Veeva Basics

Standardizing Biotechnology Processes with Veeva Basics

In the fast-paced world of biotechnology, where efficiency and innovation are crucial for success, more than 175 emerging companies are turning to Veeva Basics to establish a robust technological foundation. Veeva Systems, listed on the NYSE and a renowned provider of cloud solutions for the life sciences, has unveiled that its pre-configured applications are helping these firms streamline their operations, all while maintaining a focus on rapid drug development.

With the integration of Veeva Basics, companies are significantly reducing the time from initial concept to commercialization. These pre-validated and scalable applications allow biotechs to implement essential tools in a matter of weeks, enabling them to shift from outdated paper processes to modern, digital solutions. For instance, Bryan Ball, Chief Technology Operations Officer at Whitehawk Therapeutics, highlights the shift as transformative: “Our partnership with Veeva has allowed us to transition from paper-based processes to industry-leading solutions without the need for a dedicated IT team or complex customizations.” This improvement is particularly vital for firms specializing in challenging therapies, such as antibody-drug conjugates aimed at hard-to-treat cancers.

Enhancing Regulatory Efficiency

One of the notable capabilities of Veeva Basics is its support for regulatory publishing. With the rising complexity of regulatory requirements, many biotech companies are moving away from outsourcing their submission strategies. Veeva Submissions Publishing Basics offers a comprehensive application designed to facilitate the creation of submission packages and streamline interactions with health authorities. As observed by Darryl Clarke, Global Regulatory Operations Director at Structure Therapeutics, this shift has produced more rigorous quality controls and drastically cut down on regulatory timelines.

“By managing our submissions internally with Veeva Basics, we achieved faster regulatory timelines and enhanced control over our quality processes,” he remarked. This level of control is pivotal for companies preparing to submit their first applications to the FDA, enabling greater visibility and continuous oversight throughout the regulatory cycle.

Innovating at the Speed of Industry

The biotechnology landscape is continuously evolving, and with that evolution comes the need for corresponding technological advancements. Jim Thai, Vice President of Veeva Basics, emphasizes the importance of adaptable technology: “Biotech companies are responsible for much of the innovation shaping the industry and need technology that matches their operational pace.” Veeva Basics provides that necessary flexibility, ensuring companies can scale their infrastructure as they grow.

The applications built upon the Vault Platform are not just efficient; they are perfectly designed to adapt alongside customers as they expand. This adaptability is crucial in an industry where the landscape can shift overnight with new discoveries and advancements.

Looking Ahead: Join the Veeva Community

As Veeva continues to support the growth and success of emerging biotechs, it invites professionals in life sciences to explore its capabilities firsthand. An upcoming R&D and Quality Summit is scheduled for October 20-21 in Boston, where industry professionals can learn more about the impact of Veeva Basics on the biotech space.

In conclusion, the rapid adoption of Veeva Basics signifies a critical moment for the biotechnology sector. By embracing modern technological solutions, these companies are not only optimizing their processes but also equipping themselves for unprecedented growth and innovation in drug development. For more information on Veeva Basics, visit veevabasics.com.